
|Articles|October 1, 2003
ENBREL FDA APPROVED FOR EXPANDED INDICATION
The FDA approved Amgen and Wyeth Pharmaceuticals drug, Enbrel (etanercept), to inhibit the progression of structural damage in patients with active psoriatic arthritis and reduce its signs and symptoms.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001
2
Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials
3
Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT
4
French Early Access Data on Dupilumab in Pediatric Atopic Dermatitis
5


















